Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adicet BioACET +3.64%33 3-Year EBITDA Growth Rate is 15.10% as of Jun. 2026, which is 11% above its 10-year median of 13.60. GuruFocus rates ACET with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,130 Biotechnology companies, Adicet Bio ranks better than 50.27% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 15.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 22.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Adicet Bio was 15.30% per year. The lowest was -64.00% per year. And the median was 13.60% per year.
Adicet Bio (NAS:ACET) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Adicet Bio 3-Year EBITDA Growth Rate Related Terms
ACET vs ATRA, PYPD, GANX: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Adicet Bio's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adicet Bio 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adicet Bio's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Adicet Bio's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 15.10% mean?
Adicet Bio (ACET) has a 3-Year EBITDA Growth Rate of 15.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Adicet Bio and its competitors. This is 11% above median its historical median of 13.60. According to the industry distribution chart, Adicet Bio ranks #562 out of 1130 companies in the Biotechnology industry, placing it in the top 49.7%.
Is Adicet Bio's 3-Year EBITDA Growth Rate too high?
Adicet Bio's current 3-Year EBITDA Growth Rate of 15.10% is 11% above median its 10-year median of 13.60. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Adicet Bio's value of 15.10% is 1.7% above this industry median. Based on the distribution chart, Adicet Bio ranks #562 out of 1130 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Adicet Bio has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's 3-Year EBITDA Growth Rate compare to ATRA and PYPD?
According to the Biotechnology industry distribution chart, Adicet Bio ranks #562 out of 1130 companies for 3-Year EBITDA Growth Rate. This puts Adicet Bio in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. Adicet Bio's value of 15.10% is 1.7% above this benchmark. While the company's 10-year median is 13.60 vs. the industry median of 14.85, Adicet Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adicet Bio's current 3-Year EBITDA Growth Rate of 15.10% is 1.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Adicet Bio and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adicet Bio's current 3-Year EBITDA Growth Rate is 15.10%, which is 11% above median its own 10-year median of 13.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Adicet Bio (ACET) has a current 3-Year EBITDA Growth Rate of 15.10%. The current 3-Year EBITDA Growth Rate is 15.10%, which is 11% above median its 10-year median of 13.60 and 1.7% above the Biotechnology industry median of 14.85. Adicet Bio's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Adicet Bio (ACET), the current 3-Year EBITDA Growth Rate is 15.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
33GF Score
Get the complete analysis for ACET
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACET has been successfully added to your 
